Tag Archives: Principal Investigator

Business, Finance, Occupation & Industry

MOL Group and Wood Group Executives Join AspenTech OPTIMIZE™ 2013 Keynote Lineup

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

MOL Group and Wood Group Executives Join AspenTech OPTIMIZE™ 2013 Keynote Lineup

Dr. Béla Kelemen, SVP, MOL Group Supply Chain Management, and John Kearney, Technical Director, Wood Group to Share Industry Perspectives for Global Process Manufacturing and Engineering Companies

BURLINGTON, Mass.–(BUSINESS WIRE)– Aspen Technology, Inc. (NAS: AZPN) , a leading provider of software and services to the process industries, announced the addition of Dr. Béla Kelemen, Senior Vice President of MOL Group Supply Chain Management (SCM), and John Kearney, Technical Director of Wood Group, to address AspenTech’s global audience at OPTIMIZE 2013. Kelemen and Kearney join Professor George Stephanopoulos of the Massachusetts Institute of Technology (MIT), and AspenTech’s President and CEO Mark Fusco and Executive Vice President, Manolis Kotzabasakis, as headline speakers at OPTIMIZE 2013‘s opening plenary session.

Dr. Kelemen is Senior Vice President of MOL Group Supply Chain Management. Previously, he served as Senior Vice President of MOL Group Refining and Marketing and Vice President of MOL Group Refining. Before joining MOL Group, Kelemen held various senior-level sales and trading roles, including Director of Refinery & Marketing at Slovnaft, where he now serves as a board member.

John Kearney, Technical Director, Wood Group, has more than 30 years of industry experience, holding senior leadership positions in engineering, construction, and operations and maintenance. He has worked with the world’s leading Exploration & Production companies including Shell, BP and ExxonMobil.

Professor George Stephanopoulos is the Arthur D. Little Professor of Chemical Engineering at MIT, and a Principal Investigator in the Process Systems Engineering Lab. He has received numerous honors and awards over the years, and is the author of Intelligent Systems in Process Engineering: Paradigms for Product and Process Design and Chemical Process Control: An Introduction to Theory and Practice.

About the AspenTech OPTIMIZE Conference

AspenTech’s OPTIMIZE is the only conference dedicated to the exchange of engineering, manufacturing, and supply chain best practices for the process industries. OPTIMIZE brings together thought leaders, influencers, and experts from the top process manufacturers and engineering firms worldwide to share insight to reduce costs, improve margins, and increase profit using aspenONE® software.

Featuring nearly 100 real-world cases presented by AspenTech customers, OPTIMIZE 2013 will take place in Boston from May 6-8. Sponsors and media partners include Microsoft, AIChE, Applied Control

From: http://www.dailyfinance.com/2013/04/11/mol-group-and-wood-group-executives-join-aspentech/

Business, Finance, Occupation & Industry

Lightlake Therapeutics Announces Phase II Clinical Trial Results of Treatment for Binge Eating Disor

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Lightlake Therapeutics Announces Phase II Clinical Trial Results of Treatment for Binge Eating Disorder Accepted at the American Psychiatric Association Annual Meeting

LONDON–(BUSINESS WIRE)– Lightlake Therapeutics Inc. ( OTCBB: LLTP) (the “Company” or “Lightlake”), an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company’s Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder (BED) has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

The abstract, entitled “Opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED): Controlled Randomized Study, will be presented by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.

Dr. Roger Crystal, Chief Executive Officer of Lightlake, commented, “We are pleased that our Phase II study was accepted by this most prestigious medical organization. We believe intranasal naloxone is a truly differentiated treatment for BED, one of the major causes of obesity and the most chronic and common of all eating disorders, because it extinguishes the harmful eating behavior.”

About the Trial

The randomized, double-blind, placebo-controlled Phase II study assessed the efficacy, safety and tolerability of intranasal naloxone in 127 adults who met DSM-IV-TR® criteria for a diagnosis of binge eating disorder. The study duration was 24-weeks. Patients were randomized to intranasal naloxone (2 mg before each binge, max daily 4 mg) or placebo nasal spray. The two co-primary efficacy endpoints were the mean minutes spent binge eating and the mean scores on the standard Binge Eating Scale (BES). Overall, 81% of patients completed the entire six month study, and there were no Serious Adverse Events (SAE).

Patients in the naloxone group showed a statistically significant 75.2% reduction in binge eating. The trial EudraCT registry # is 2010-019892-31 and is also registered at ClinicalTrials.gov. The study was sponsored by Lightlake Therapeutics Inc.

About Naloxone

Naloxone an opioid antagonist that blocks the brain’s opioid receptors for a short length of time. It is not an appetite suppressant, nor does it prevent the body from absorbing fat, but rather deals with the physiological and psychological underpinnings that cause cravings for foods high in fat, salt or sugar. Intranasal naloxone is absorbed within minutes, and over time, results in the extinction …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Affymetrix Signs Contract With UK Biobank to Genotype 500,000 UK Individuals in the Largest Ever Stu

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Affymetrix Signs Contract With UK Biobank to Genotype 500,000 UK Individuals in the Largest Ever Study of Genetic and Environmental Factors in Disease and Personalized Medicine

SANTA CLARA, Calif.–(BUSINESS WIRE)– Affymetrix, Inc. (NAS: AFFX) today announced that it has signed a contract with UK Biobank to genotype 500,000 DNA samples donated by UK residents as part of a prospective epidemiological study of complex diseases that are of great relevance to public health. Affymetrix’ Axiom® Genotyping Solution will be used to generate billions of high-quality genotypes which will provide UK Biobank and the research community with valuable insight to genetic factors underlying human diseases for improved prevention, diagnosis, and treatment of conditions such as heart disease, cancer, and diabetes.

Professor Rory Collins, UK Biobank CEO and Principal Investigator said: “UK Biobank is pleased to join forces with Affymetrix for this next phase of the UK Biobank project. The two organizations will work closely together to ensure that world class data are provided quickly and securely to help scientists working on the causes of a wide range of life-threatening and disabling diseases. I urge health scientists everywhere to think carefully about how this resource could be used to help their research, and to register with UK Biobank. I am also very grateful to the half a million participants whose generosity and vision for the future has allowed this resource to grow.”

“We are honored to partner with UK Biobank on this mission critical research initiative,” said Dr. Frank Witney, President and CEO of Affymetrix. “Earlier this year, we outlined our strategy to broaden our reach into the translational medicine, molecular diagnostics, and applied markets as part of our long-term transformation plan. This partnership reflects our efforts to strengthen our position in the growing translational medicine market and our commitment to work with visionary organizations such as the UK Biobank to produce the next generation of biological information that will improve healthcare.”

“Large scale genotyping studies such as the one undertaken by UK Biobank demand a flexible and scalable genomics analysis technology that produces a large amount of high quality data quickly, consistently, and cost-effectively. The unmatched flexibility, array reproducibility, and advanced design capabilities were key factors in UK Biobank adopting the Axiom Genotyping Solution. These platform capabilities have become increasingly important for genotyping studies in both the human and agbio markets as requirements shift away from very high-density, standardized designs toward customized high-fidelity arrays. We are very proud that our Axiom Genotyping Solution has been chosen for this incredibly important project,” said Dr. Andy …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Results of Lymphoseek® Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Onco

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Results of Lymphoseek ® Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Oncology


– Lymphoseek Meets Primary Efficacy Endpoint in Assessment of Lymphatic Mapping Performance in Patients with Breast Cancer –

DUBLIN, Ohio–(BUSINESS WIRE)– Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostic radiopharmaceuticals, today announced the peer-reviewed publication of results from two Phase 3 clinical trials of Lymphoseek® (technetium 99m tilmanocept) Injection in patients with breast cancer. The trials assessed the performance of Lymphoseek against the standard of care, vital blue dye (VBD), in lymphatic mapping. Results demonstrated that Lymphoseek met its primary efficacy endpoint of rate of agreement, or concordance, with VBD. The study, “Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials,” was published in the current online edition of the journal Annals of Surgical Oncology [DOI 10.1245/s10434-013-2887-8].

Lymphoseek is a receptor-targeted radiopharmaceutical recently approved by the U.S. Food and Drug Administration and indicated for use in lymphatic mapping for breast cancer and melanoma. In this procedure key lymph nodes adjacent to a primary tumor, that may contain tumor metastases, are identified and biopsied to determine if cancer has spread to these lymph nodes.

“Lymphoseek was specifically designed to provide clinicians who perform lymphatic mapping procedures with actionable information, and we believe that the data reported in this publication demonstrate its utility and safety in identifying tumor-draining lymph nodes,” said Frederick Cope, Ph.D., Senior Vice President, Pharmaceutical Research and Clinical Development of Navidea. “These data from breast cancer patients, in conjunction with previously published data from our Phase 3 clinical trials in melanoma, comprise part of our NDA registration package for Lymphoseek with the FDA. We are confident that Lymphoseek may hold significant improvement for patients who undergo lymphatic mapping procedures.”

“Tilmanocept was originally developed at UCSD as a targeted molecular approach to help stage breast cancer and melanoma patients, and we advanced the agent through Phase 1 clinical trials with funding provided by Susan G. Komen Breast Cancer Foundation and the American Cancer Society,” said Anne Wallace, M.D., Chief, Division of Plastic Surgery; Professor of Surgery, UC San Diego School of Medicine; Director of the Breast Care Unit; UC San Diego Moores Cancer Center; and a Principal Investigator in the Lymphoseek Phase 3 clinical trials. “The results from these Phase 3 clinical trials …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Data on Provectus's PV-10 to Be Presented at the HemOnc Today – Melanoma and Cutaneous Malignancies

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Data on Provectus’s PV-10 to Be Presented at the HemOnc Today – Melanoma and Cutaneous Malignancies Conference on March 22, 2013

KNOXVILLE, Tenn.–(BUSINESS WIRE)– Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that data on PV-10 for metastatic melanoma will be included in a presentation at the HemOnc Today – Melanoma and Cutaneous Malignancies Conference on Friday, March 22, 2013 in New York.

Dr. Robert H.I. Andtbacka, Assistant Professor of Surgical Oncology, Huntsman Cancer Institute at the University of Utah in Salt Lake City, is scheduled to present during conference session on Local-Regional Therapy. His presentation, “Current Status of Injectable Therapy” begins at 1:55 p.m., EDT. This session will be moderated by Sanjiv S. Agarwala, MD, Principal Investigator for the Phase 2 trial of PV-10, and Chief of Medical Oncology and Hematology at St. Luke’s Hospital and Health Network in Bethlehem, PA.

Dr. Craig Dees, PhD, CEO of Provectus said, “We are pleased to be participating in this important conference. We expect Dr. Andtbacka’s presentation will support PV-10’s utility in the treatment of metastatic melanoma.”

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company’s website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

'SuperTruck' Yields 54 Percent Increase in Fuel Economy

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

‘SuperTruck’ Yields 54 Percent Increase in Fuel Economy

COLUMBUS, Ind.–(BUSINESS WIRE)– Cummins Inc. (NYS: CMI) and Peterbilt Motors Company, a division of PACCAR (NAS: PCAR) , released test results today showing their demonstration tractor-trailer achieved a 54 percent increase in fuel economy, averaging nearly 10 miles per gallon (mpg) under real world driving conditions.

The “SuperTruck” developed by the two companies features a higher-efficiency engine and an aerodynamic tractor-trailer that significantly reduces drag. The truck also includes a system that converts exhaust heat into power delivered to the crankshaft, electronic controls that use route information to optimize fuel use, tires with lower rolling resistance and lighter-weight material throughout.

The Class 8 Peterbilt 587 powered by a Cummins ISX15 engine averaged 9.9 mpg during testing last fall on U.S. Route 287 between Fort Worth and Vernon, Texas. The testing was conducted over 11 runs meeting SAE International test standards along a 312-mile route. The tractor-trailer had a combined gross weight of 65,000 lbs.

Today’s long-haul trucks typically achieve between 5.5 and 6.5 mpg. The 54 percent increase in fuel economy would save about $25,000 annually based on today’s diesel fuel prices for a long-haul truck traveling 120,000 miles per year. It would also translate into a 35 percent reduction in annual greenhouse gases per truck.

The potential savings in fuel and greenhouse gases are enormous, with about 2 million registered tractor-trailers on U.S. roads today, according to The American Trucking Association.

In addition to the fuel economy improvements, the truck also demonstrated a 61 percent improvement in freight efficiency during testing compared to a baseline truck driving the same route. That significantly exceeded the 50 percent SuperTruck program goal set by the U.S. Department of Energy. Freight efficiency is an important metric in the transportation industry that is based on payload weight and fuel efficiency expressed in ton-miles per gallon.

“Many of the technologies we are testing on the engine and truck will be integral parts of the trucks of tomorrow,” said David Koeberlein, Principal Investigator for the SuperTruck program at Cummins. “We are focused on developing innovations that meet and exceed the needs of our customers, while helping to create a cleaner, healthier and safer environment.”

Cummins personnel have been focused on the engine and its integration with the powertrain. They have been working with several other companies and research institutions to develop numerous changes in the combustion system …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

FDA Approves Navidea's Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Use in Lymphatic Ma

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

FDA Approves Navidea’s Lymphoseek ® (technetium Tc 99m tilmanocept) Injection for Use in Lymphatic Mapping

The first receptor-targeted radiopharmaceutical approved for lymphatic mapping in breast cancer and melanoma patients


Company to Host Conference Call at 4:00 p.m., March 13, 2013

DUBLIN, Ohio–(BUSINESS WIRE)– Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of Lymphoseek® (technetium Tc 99m tilmanocept) Injection, a novel product indicated for use in lymphatic mapping procedures to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma. Lymphoseek is a receptor targeted radiopharmaceutical designed to identify these lymph nodes which have the highest probability of harboring cancer and thereby assist physicians in the staging of such patients.

Lymphatic mapping is a procedure in which lymph nodes that may contain tumor metastases are identified and biopsied to determine if cancer has spread beyond the primary tumor. Accurate staging of lymph nodes is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. According to the American Cancer Society, approximately 232,000 new cases of breast cancer and 77,000 new cases of melanoma are expected to be diagnosed in the United States in 2013.1

“We recommend lymphatic node mapping and sentinel node biopsy for patients with early stage breast cancer and in select cases of ductal carcinoma in situ,” said Anne Wallace, M.D., Professor of Surgery, UC San Diego School of Medicine; Director of the Breast Care Unit; UC San Diego Moores Cancer Center; and Principal Investigator for breast cancer in the Lymphoseek Phase 3 clinical trials. “The ability to reliably identify multi-node pathology-positive patients is important to optimize their post-surgery management and to spare certain patients from unnecessary surgery and potentially debilitating side effects. Products specifically designed to address reliable lymph node uptake and retention can provide significant clinical utility and help standardize the process of lymph node mapping.”

“Both the incidence rate and the death rate for melanoma continue to increase, in the United States and in many other parts of the world,” said Vernon K. Sondak, M.D., Chair, Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa Fla., and Principal Investigator for melanoma in the Lymphoseek Phase 3 clinical trials. “Most patients present …read more
Source: FULL ARTICLE at DailyFinance